Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New nasal device aims to quiet chronic runny nose

NCT ID NCT05937308

Symptom relief Sponsor: Neurent Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study is tracking 150 adults with chronic rhinitis (long-term runny nose and congestion) who are receiving treatment with the NEUROMARK device. The device uses radiofrequency energy to disrupt nerves in the nose, aiming to reduce symptoms. Researchers are collecting real-world data on safety and how well it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NEUROMARK System (a device that uses radiofrequency energy to disrupt nasal nerves)
What this could lead to
If successful, this could confirm that the NEUROMARK device is a safe and effective option for reducing chronic rhinitis symptoms like runny nose and congestion.
What could go wrong
This is a single-arm registry, not a randomized trial, so results may be less definitive. There is a risk of side effects from the procedure, such as pain or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subject MUST: 1. Be ≥18 years of age. 2. Be scheduled to receive treatment with the commercially available NEUROMARK System consistent with the device's indications for use. 3. Have moderate to severe symptoms of running nose (individual rTNSS symptom rating of 2 or 3), mild to severe symptoms of nasal congestion (individual rTNSS symptom rating of 1, 2, or 3), and a minimum total score of 5 (out of 12) at screening. 4. Be willing and able to provide consent and comply with all study elements, as indicated by written informed consent. Exclusion Criteria: Subjects Must Not: 1\. Have a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic rhinitis rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinitis

Contacts and locations

Locations

  • Alabama Nasal & Sinus Center

    Birmingham, Alabama, 35242, United States

  • Breathe Clear Institute

    Torrance, California, 90503, United States

  • ENT & Allergy Texas

    McKinney, Texas, 75071, United States

  • Florida ENT & Allergy

    Brandon, Florida, 33511, United States

  • Kentuckiana ENT

    Louisville, Kentucky, 40205, United States

  • Metropolitan ENT

    Alexandria, Virginia, 22310, United States

  • Ogden Clinic

    Ogden, Utah, 84403, United States

  • Sacramento ENT

    Roseville, California, 95661, United States

  • Sensa Health

    Los Angeles, California, 90006, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.